NasdaqGS:MRNABiotechs
Moderna (MRNA) Adds Finance Veteran To Its Board, Is The Stock Fully Valued?
Moderna (MRNA) shares are back in focus after the company appointed veteran finance executive Michael McDonnell to its Board and Audit Committee, and reshuffled committee roles as part of broader governance adjustments.
See our latest analysis for Moderna.
At a share price of $59.66, Moderna has seen a 93.32% year to date share price return and an 82.28% total shareholder return over one year. However, the 3 year and 5 year total shareholder returns have declined 51.05% and 81.84%...